Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference


Posted on: 14 Mar 18

YONKERS, New York, March 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that Cara Cassino, M.D., the Company’s Chief Medical Officer and Executive Vice President of Research and Development, will present at the 20th Annual Superbugs & Superdrugs Conference in London, UK. The focus of the presentation will be on ContraFect’s lead program, CF-301, which is currently being studied in an ongoing Phase 2 clinical trial as a potential treatment for Staphylococcus aureus (Staph aureus) bacteremia, including endocarditis.

Presentation Details:

Presentation Title: Lysins: Alternative Antimicrobials to Improve Clinical Outcomes Serious Bacterial Infections - CF-301 - A Case Study

Session Day & Time: Tuesday, March 20, 2018 2:40 PM GMT (10:40 AM ET)

Key Topics Covered:

  • CF-301 demonstrates the hallmark features of lysins, including: rapid, targeted bacteriolysis, potent synergy with conventional antibiotics, activity against antibiotic-resistant strains, low propensity for resistance and remarkable biofilm eradication.
  • Animal studies of CF-301 demonstrate the therapeutic potential of lysins to boost the efficacy of conventional antibiotics and combat antimicrobial resistance.
  • The CF-301 clinical development program is designed to evaluate the potential of lysin therapeutics to treat serious, invasive, biofilm-associated bacterial infections due Staph aureus.

About ContraFect:
ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (Methicillin-resistant Staph aureus) and influenza. ContraFect’s lead product candidate, CF-301, is currently in a Phase 2 clinical trial for the treatment of Staphylococcus aureus bacteremia, including endocarditis and is the first lysin to enter clinical studies in the U.S.  ContraFect is also conducting research focused on the discovery of lysins to target Gram-negative bacteria.

Forward-Looking Statements:
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws.  Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding our ability to discover and develop protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, our ability to address life threatening infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses, whether our initial product candidates can treat antibiotic-resistant infections such as MRSA and influenza, our ability to discover new lysins targeting Gram-negative bacteria, the potential for CF-301 to be a treatment for Staph aureus bacteremia, including endocarditis, and statements made regarding CF-301 in key presentation topics. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including those detailed in ContraFect's filings with the Securities and Exchange Commission.  Actual results may differ from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, among others, our ability to develop treatments for drug-resistant infectious diseases. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations Contacts:
Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com 

Matthew Shinseki
Stern Investor Relations
Tel: 212-362-1200
Email: matthew@sternir.com 

 

GlobeNewswire
globenewswire.com

Last updated on: 14/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.